Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 17, 2015 07:00 ET | Source: Celsus Therapeutics

Celsus Therapeutics Announces That the Phase II Trial of MRX-6 Cream 2% in Pediatric Atopic Dermatitis Did Not Reach Primary Endpoint

NEW YORK and LONDON, Feb. 17, 2015 (GLOBE NEWSWIRE) -- Celsus Therapeutics (Nasdaq:CLTX), an emerging growth, development-stage biopharmaceutical company, announced today the results from C012013, a...
January 13, 2015 07:00 ET | Source: Celsus Therapeutics

Celsus Therapeutics Completes Enrollment of Phase II Trial of MRX-6 Cream 2% in Pediatric Atopic Dermatitis

NEW YORK and LONDON, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Celsus Therapeutics (Nasdaq:CLTX), an emerging growth, development-stage biopharmaceutical company, announced today that the Company has...
January 12, 2015 07:00 ET | Source: Celsus Therapeutics

Celsus Therapeutics Announces FDA Allowance of IND for Clinical Development of MRX-6 Cream in Atopic Dermatitis

NEW YORK and LONDON, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Celsus Therapeutics (Nasdaq:CLTX), an emerging growth, development-stage biopharmaceutical company, announced today that the U.S. Food and Drug...
December 02, 2014 07:30 ET | Source: Celsus Therapeutics

Celsus Therapeutics Announces Upcoming Presentation at Oppenheimer 25th Annual Healthcare Conference

NEW YORK and LONDON, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics (Nasdaq:CLTX), an emerging growth, development-stage biopharmaceutical company, announces that Gur Roshwalb, MD, chief...
August 06, 2014 07:30 ET | Source: Celsus Therapeutics

Celsus Therapeutics Plc Announces First Patient Enrolled in Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis

NEW YORK and LONDON, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced the first patient has been enrolled in its...
June 17, 2014 07:10 ET | Source: Celsus Therapeutics

Celsus Therapeutics Plc Receives Approval From the Ministry of Health of Israel for Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patients

NEW YORK and LONDON, June 17, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, has received approval from the Israeli Ministry of...
May 14, 2014 16:05 ET | Source: Celsus Therapeutics

Celsus Therapeutics PLC Announces Details of Annual General Meeting of Shareholders

NEW YORK and LONDON, May 14, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today that the annual general meeting of...
April 07, 2014 07:30 ET | Source: Celsus Therapeutics

Celsus Therapeutics Plc Announces Formation of New Dermatology Scientific Advisory Board

NEW YORK and LONDON, April 7, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today the formation of a new Dermatology...
March 31, 2014 16:05 ET | Source: Celsus Therapeutics

Celsus Therapeutics Plc to Present at the 13th Annual Needham Healthcare Conference

NEW YORK and LONDON, March 31, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today that Dr. Gur Roshwalb, Chief...
March 24, 2014 16:05 ET | Source: Celsus Therapeutics

Celsus Therapeutics Provides Year End 2013 Financial Results and Corporate Highlights

NEW YORK and LONDON, March 24, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, today announced its financial results and provided...